UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Bates RL, Payne SJ, Drury SL, Nelson PN, Isenberg DA, Murphy JJ, Frampton G
  • Publication date:
    2003
  • Pagination:
    617, 622
  • Journal:
    Lupus
  • Volume:
    12
  • Issue:
    8
  • Print ISSN:
    0961-2033
  • Keywords:
    activity, As, Autoantibodies, clinical, control, Correlation, disease, FREQUENCIES, FREQUENCY, global, HYPOTHESIS, IM, Immunoassay, INDEX, INHIBITOR, LA, Longitudinal, Longitudinal Studies, longitudinal study, Lupus, May, novel, PARAMETER, PARAMETERS, Patient, patients, Plasminogen Activator Inhibitor 1, play, Prevalence, recombinant, serum, SLE, support, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS
  • Notes:
    DA - 20030829 IS - 0961-2033 LA - eng PT - Journal Article SB - IM
Abstract
We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by